Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results – Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...

Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19 – Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the...

Novan to Report Third Quarter 2021 Financial Results on November 10, 2021 DURHAM, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday,...

Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program – Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the...

Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update – Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating...